U.S. Cancer Biomarker Market Size & Outlook, 2026-2033

Name: U.S. Cancer Biomarker Market Size & Outlook
Creator: Grand View Research
License: https://www.grandviewresearch.com/horizon/info/terms-of-use

The cancer biomarker market in the United States is expected to reach a projected revenue of US$ 22,800.1 million by 2033. A compound annual growth rate of 11% is expected of the United States cancer biomarker market from 2026 to 2033.

Clinical Diagnostics
- In Vitro Diagnostics
  - Cancer Biomarker Market Outlook

U.S. cancer biomarker type outlook (Revenue, USD million, 2021-2033)
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Others
U.S. cancer biomarker biomolecule outlook (Revenue, USD million, 2021-2033)
- Genetic Biomarkers
- Epigenetic Biomarkers
- Metabolic Biomarkers
- Proteomic Biomarkers
U.S. cancer biomarker application outlook (Revenue, USD million, 2021-2033)
- Drug Discovery and Development
- Diagnostics
- Personalized Medicine
U.S. cancer biomarker technology outlook (Revenue, USD million, 2021-2033)
- Polymerase Chain Reaction (PCR)-based Technologies
- Next-Generation Sequencing (NGS)-based Technologies
- Immunoassay-based Technologies
- In Situ Hybridization (ISH) & Cytogenetic Technologies
- Mass Spectrometry-based Technologies
- Imaging-based Biomarker Technologies

U.S. Cancer Biomarker Market Size & Outlook, 2026-2033

Data Tree

Sign up - it's easy, and free!